Table 2.
Author (year) | Study design | Country | Year range for data collection | Measures reported | Inclusion criteria | Study population and patient characteristics |
---|---|---|---|---|---|---|
Marsh et al. (2021) [18] | Patient preference elicitation study | USA and China | NR | An interview-based swing weighting approach to assess patient preference elicitation | To be eligible, participants had to be ≥ 18 years of age at the time of consent, self-report having biopsy-verified primary IgAN, currently receiving ACEi/ARBs for at least 6 months, and be fluent in English (in the USA) or Mandarin (in China) |
Population USA, n = 25; China, n = 15 Mean age: 41.6 years Race/ethnicity (US population): 68% Caucasian; 16% Latino; 12% Black/African American; 4% Asian Sex: 32.5% male; 67.5% female |
Mizerska-Wasiak et al. (2021) [19] | Multicenter cross-sectional study | Poland | 2000–2015 |
Kidscreen-52 questionnaire The Anger Expression Scale The Personal Competence (KompOs) Scale |
Patient age ≥ 8 years, no disease exacerbation during the last 3 months, and written informed consent for study participation |
Population: n = 51 Mean age: 15.5 years Mean duration of IgAN: 5 years Patients with hematuria/proteinuria: 76.5% |
Zhao et al. (2020) [20] | Prospective observational | China | 2013–2018 |
The Beck Depression Inventory-II (BDI-II) Eysenck Personality Questionnaire (EPQ) Quality of Life Index (QLI) Life Satisfaction Index (LSI) Short Form-36 (SF-36) |
(1) Adults (age > 18 years); (2) patients who were diagnosed with IgAN on renal biopsy; and (3) Beck Depression Inventory-II (BDI-II) score > 14 |
Population: Physical activity (PA), n = 108; no intervention (NI) n = 108 Mean age: PA: 56.1 years; NI: 58.1 years Sex: PA: 62% female; NI: 58.3% female Receiving dialysis: PA: 35.2%; NI: 38.9% |
NR not reported, ACEi/ARBs angiotensin-converting enzyme inhibitors/ angiotensin receptor blockers, GN glomerulonephritis, BC British Columbia, HRU healthcare resource use, ESKD end-stage kidney disease